GlassScriptPhysician profile
Kimberly A Thompson
NPI 1487605267
$1,978.92
in general payments reported to CMS, 2019-2025
29 companies · $980 in 2025
The $980 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2021: $42.07 · 2022: $33.32 · 2024: $821 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $350.35 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $217.60 | 2024-2025 | |
| Lilly USA, LLC | $208.39 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $131.22 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $116.62 | 2024-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $103.33 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $102.56 | 2019 | |
| Boston Scientific Corporation | $73.55 | 2022-2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $70.00 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $57.19 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $56.21 | 2024 | |
| Amgen INC. | $54.57 | 2024-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $44.45 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Shield Therapeutics INC | $42.85 | 2024-2025 | |
| Eisai INC. | $42.07 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $36.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.92 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $24.54 | 2024 | Nexletol |
| Sumitomo Pharma America, INC. | $23.97 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $23.57 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.90 | 2025 | Caplyta |
| Abbott Laboratories | $21.68 | 2024 | Freestyle Libre 3 |
| Si-Bone, INC. | $20.81 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $19.32 | 2025 | Neffy |
| Acella Pharmaceuticals, LLC | $17.62 | 2025 | NP Thyroid 60 |
| E.R. Squibb & Sons, L.L.C. | $16.89 | 2025 | Camzyos |
| Exact Sciences Corporation | $16.54 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $15.61 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $14.16 | 2024 | Capvaxive, M-M-R II, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.